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Previewselegantly put these concepts together in a
comprehensive picture that is highly rele-
vant from a clinical standpoint. In other
words, if there’s something strange and
you don’t feel good, who ya gonna call?
IL-23, not IL-17, might be the real Gut-
Buster.
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Whereas dendritic cells (DCs) can be activated in many ways to trigger immunity, hardly anything is known
about the mechanisms that counterbalance DC activation. Cyster and colleagues now demonstrate that the
‘‘self’’ molecule CD47 on erythrocytes critically restricts splenic DC activation.Since the pioneering work on antibodies
by Paul Ehrlich (Ehrlich, 1891) and the
discovery of the ABO blood group sys-
tem by Karl Landsteiner (Landsteiner,
1900), immunology as a science has
come a long way. Over the years, foreign
red blood cells (RBCs) have continued to
be a favorable antigenic agent for
inducing immunity and for studying the
functioning of the immune system. This
was not only because antibody re-
sponses could easily be measured, e.g.,
by Landsteiner’s hemagglutination as-
says, but also because such RBCs
generate robust immune responses
(Kraal et al., 1982). However, the basis
for this strong immunogenicity of foreign
RBCs has remained essentially elusive.
The paper by Yi et al. in this issue of Im-
munity (Yi et al., 2015) describes a series
of elegant experiments that reveal why
xenogeneic RBCs induce such strong
immune responses. The study focuses
primarily on the activation of CD4-posi-
tive dendritic cells (DCs) in the spleen.These CD4+ DCs are known to play a
key role in the activation of CD4 follicular
helper cells and the triggering of the
germinal-center reaction, which in turn
will drive antibody responses. First, it
was demonstrated that immunization of
mice with xenogeneic RBCs (in this
case sheep RBCs), but not with synge-
neic RBCs, stimulated CD4+ DC activa-
tion. Subsequently, the authors turned
their attention to the mechanism underly-
ing this species-specific phenomenon,
and in particular, to the role of interac-
tions between CD47 and the inhibitory
immunoreceptor signal regulatory protein
a (SIRPa), both of which are actually well
known to act in a species-specific
fashion (Barclay and Van den Berg,
2014). CD47 on erythrocytes and other
cells has previously been identified as a
signal of ‘‘self,’’ and the lack of CD47
on RBCs leads to a very rapid clearing
of these cells by macrophages in vivo
(Oldenborg et al., 2000). This is because
CD47 interacts with SIRPa on macro-phages and acts as a ‘‘don’t eat me’’
signal to prevent phagocytosis (Barclay
and Van den Berg, 2014). However,
because CD4+ DCs also express SIRPa,
and because splenic DCs might directly
interact with circulating RBCs in the mar-
ginal zone, where many of these DCs are
localized in the so-called marginal-zone
bridging channels, it was reasoned that
direct CD47 and SIRPa interactions be-
tween these RBCs and DCs, respectively,
might be instrumental in the observed
dampening of DC activation. Indeed, the
injection of CD47-deficient (but not wild-
type) RBCs caused a strong CD4+ DC
activation, and this was accompanied by
migration to and accumulation of these
DCs in the T cell zones of the splenic white
pulp, where they could activate CD4+
T cells (Figure 1). The authors obtained
further evidence that CD47-SIRPa inter-
actions were in fact involved by injecting
blocking antibodies against SIRPa. More-
over, the lack of CD47 on RBCs promoted
the induction of antigen-specific CD4+
Figure 1. Signaling Controls RBC Phagocytosis and CD4+ DC Activation in the Splenic
Marginal Zone
(A) Under normal homeostatic conditions, CD47 prevents CD4+ DCs from phagocytosing RBCs by
signaling through SIRPa.
(B) RBCs lacking CD47 or xenogeneic RBCs whose CD47 is unable to bind to SIRPa are subject to
phagocytosis bymarginal-zone CD4+DCs. This then causes, or is at least accompanied by, DC activation,
resulting in the expression of MHCII, CD86, and CCR7 on the CD4+ DCs and their subsequent migration to
the T cell zone, where these activated DCs can support CD4+ T cell proliferation and differentiation.
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PreviewsT cell responses, at least when the antigen
was physically associated with the eryth-
rocytes. In addition to lacking self-CD47
molecules on their surface, foreign RBCs
likewise carry their own antigenic compo-
nents as well.
While the studyprovides, at least in part,
an explanation for the potent immune re-
sponses that can be evoked by foreign
erythrocytes, it actually contributes
considerably more to our understanding
of the immune system. Clearly, the most
exciting, and perhaps rather unexpected,
implication of the study is that RBCsmight
play an essential andactually quite power-
ful role in controlling the activation of
splenic DC. It should be noted that the po-
tency of the phenomenon is quite striking,
given that, in a sea of normal CD47-car-
rying RBCs, as little as 5 ml of CD47-defi-
cient RBCs (<0.5% of the total) could
cause a detectable response. This sug-
gests that there must be a very strong
DC-activating signal associated with the
RBCs. In an attempt to obtainmore insight
into the nature of this RBC-derived acti-
vating signal andalso into theway thispre-
sumed activity is sensed by theDC, the in-vestigators evaluated a potential role for
tyrosine kinase signaling in splenic CD4+
DC activation by RBC lacking CD47.
Conceptually this makes sense, given
that SIRPa can signal via the cytosolic
tyrosine phosphatases SHP-1 and/or
SHP-2 (Barclay and Van den Berg, 2014).
Indeed, by using mixed bone marrow
chimeric recipients, Yi and colleagues
demonstrated that DC-intrinsic activity of
tyrosine kinases, including Src-kinases
and to a lesser extent also Syk, were
important. Also, it appeared that DC
beta-2 (b2) integrins (CD18) were critical.
The latter is of interest because erythro-
cytes express the b2-integrin ligand
ICAM-4. However, without disclosing de-
tails, the authors claim that they have ruled
out an involvement for this molecule. It
seems nevertheless possible that b2-in-
tegrins, of which different types, including
CD11a/CD18, CD11b/CD18 and CD11c/
CD18, are expressed by murine CD4+
DCs, are themselves involved in the
recognition of some unknown ligand on
the RBCs. Alternatively, CD18 could
cooperate in such recognition and/or in
the accompanying uptake process.Immunity 43Thus, the question of the presumed acti-
vating stimulus on the RBCs and its
sensing by DCs remains essentially an
open one that deserves further attention.
In any case, it seemsclear from thecurrent
findings that at least one level at which
CD47-SIRPa interactions act in this
context is at that of the endocytic uptake
of RBC material, and this is clearly also
consistent with the well-established role
of CD47 as a ‘‘don’t eat me’’ signal (Bar-
clay and Van den Berg, 2014). A relevant
related question is whether the presumed
activating DC surface receptor for RBCs
would also directly transmit the signals
that lead to DC activation or whether a
downstream endocytic accumulation of
other RBC-associated danger signals
(e.g., heme?) in the DC would be respon-
sible for this. If indeed there is such a
requirement for RBC uptake, this might
in fact also explain the finding that already
small amounts of highly diluted CD47-
deficient RBC can efficiently trigger the
DC activation response.
The findings by Yi et al. might also be
useful for understanding the DC pheno-
type observed in CD47- and SIRPa-defi-
cient mice (Barclay and Van den Berg,
2014). In both genotypes, there appeared
to be a strong and selective reduction in
the numbers of CD4+ DC (to 30% of
wild-type levels), and this could be
caused by chronic activation that could
well lead to an exhaustion of these CD4+
DC, evident by a selective reduction of
their numbers, and a consequent impair-
ment in such mice to mount appropriate
T cell responses. Importantly, this could
in turn provide an explanation for the
resistance to T-cell-mediated autoimmu-
nity that is observed is the absence of
CD47 or SIRPa, and this might, among
other things, also explain the lack of a
CD4+ T-cell-mediated host defense
against Salmonella infection (Barclay and
Van den Berg, 2014). What is puzzling,
however, as the authors point out them-
selves as well, is that the reduction in
CD4+ DCs is not only observed in the
spleen, but also in lymph nodes and
Peyer’s patches, where DCs are not
exposed to a strong and direct flow of
RBCs (Barclay and Van den Berg, 2014).
This opens up the possibility that the
lack of CD47 on other cells might also
contribute to this. In this context, the
question perhaps arises, to what extent
does this study formally prove that RBCs, October 20, 2015 ª2015 Elsevier Inc. 623
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Previewstrigger the DC activation response? For
one thing, white blood cells injected alone
were apparently unable to evoke CD4+
DC activation, as shown, but more inves-
tigation is needed to further substantiate
that RBCs are both essential (platelets?
white cell contribution?) and sufficient
(highly purified RBCs?) for this. The cur-
rent work certainly deserves credit for
providing the inspiration to perform such
studies.
Another question relates to the issue of
‘‘missing self.’’ Clearly, this concept is
well known for MHC class I molecules
that can be downregulated under various
pathological conditions, such as infection
with large DNA viruses. However, is this
also the case for CD47 on RBCs? And if
so, could this then be a mechanism to
engage erythrocytes in promoting immu-
nity by delivering danger signals to DCs?
Actually, we do not really know at this
point whether missing CD47 occurs at
all, for instance, during infections of the
erythrocyte, and, if this does occur,
whether it plays a critical and meaningful
role. Clearly, one condition that springs
to mind when considering erythrocytes
as a target for infection is malaria. Howev-624 Immunity 43, October 20, 2015 ª2015 Eler, evidence so far has not revealed any ef-
fects of RBC Plasmodium infection on
CD47 overall expression (Hempel et al.,
2014). What is interesting nevertheless is
that CD47 deficiency confers resistance
to malaria infection (Banerjee et al.,
2015), and the current work by Yi et al.
might also provide a potential explanation
for that.
Finally, there is the situation in humans.
It is known that the human spleen has
quite a different architecture than the ro-
dent spleen, and this is particularly
evident in the marginal-zone area. In
fact, a marginal zone is not clearly identifi-
able in the human spleen (Steiniger,
2015). Nevertheless, the perifollicular
zone of the human spleen, which also
contains a subset of DCs, has been sug-
gested to resemble, at least in some as-
pects, the rodent marginal zone (Pack
et al., 2008). It would obviously be of inter-
est to find out whether this novel and
exciting concept of RBC-mediated con-
trol over DC activation also occurs in hu-
mans. Be that as it may, Yi and colleagues
have certainly demonstrated that DCs see
red when encountering erythrocytes that
are denuded of CD47.sevier Inc.REFERENCES
Banerjee, R., Khandelwal, S., Kozakai, Y., Sahu,
B., and Kumar, S. (2015). Proc. Natl. Acad. Sci.
USA 112, 3062–3067.
Barclay, A.N., and Van den Berg, T.K. (2014). Annu.
Rev. Immunol. 32, 25–50.
Ehrlich, P. (1891). Dtsch. Med. Wochenschr. 32,
976–979.
Hempel, C., Kohnke, H., Maretty, L., Jensen, P.O.,
Staalsø, T., and Kurtzhals, J.A. (2014). Mol. Bio-
chem. Parasitol. 198, 29–36.
Kraal, G., Weissman, I.L., and Butcher, E.C. (1982).
Nature 298, 377–379.
Landsteiner, K. (1900). Centralblatt fur Bakteriolo-
gie, Parasitenkunde und Infektionskrankheiten
27, 357–362.
Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lage-
naur, C.F., Gresham, H.D., and Lindberg, F.P.
(2000). Science 288, 2051–2054.
Pack, M., Trumpfheller, C., Thomas, D., Park, C.G.,
Granelli-Piperno, A., Mu¨nz, C., and Steinman, R.M.
(2008). Immunology 123, 438–446.
Steiniger, B.S. (2015). Immunology 145, 334–346.
Yi, T., Li, J., Chen, W., Wu, J., An, J., Xu, Y., Hu, Y.,
Lowell, C.A., and Cyster, J.G. (2015). Immunity 43,
this issue, 764–775.Keeping Off the Weight with DCsEthan A. Edwin1 and Anthony W. Ferrante, Jr.1,*
1Department of Medicine, Naomi Berrie Diabetes Center, Columbia University, 1150 St Nicholas Ave, New York, NY 10032, USA
*Correspondence: awf7@cumc.columbia.edu
http://dx.doi.org/10.1016/j.immuni.2015.10.003
Long studied as modulators of insulin sensitivity, adipose tissue immune cells have recently been implicated
in regulating fat mass and weight gain. In this issue of Immunity, Reisner and colleagues (2015) report
that ablation of perforin-expressing dendritic cells induces T cell expansion, worsening autoimmunity and
surprisingly increasing adiposity.The immune and metabolic systems are
tightly coupled so that substantial
changes in one often alter the function
and state of the other. In adipose tissue
(AT), where these two systems interact
intimately, increases or decreases in fat
mass elicit cellular immune responses
that can increase or decrease immune
cell populations by as much as an order
of magnitude, so that in the most obeseindividuals immune cells constitute the
majority of cells in a fat depot. Conversely,
perturbations in immune cell number and
function can increase or reduce the effi-
ciency of adipocyte lipid storage, and
thereby alter systemic glucose and lipid
metabolism. Sub-populations of adipose
tissue macrophages (ATMs) and T cells
have been the most intensively studied
but eosinophils, mast cells, neutrophils,and iNKT cells also respond to changes
in the metabolic state of adipose tissue
and have been implicated in modulating
local inflammation and systemic meta-
bolism. A simple paradigm has emerged
from early studies suggesting that
changes in immune function and profiles
that skew toward a type 1 cellular immune
response impair adipocyte function and
induce systemic insulin resistance.
